TOVX — Theriva Biologics, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 894158 ·
Last close
$0.14
Market Cap
$6.42M
52W High
$0.49
52W Low
$0.14
ADV30
3,715,754
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,295,000 | -3,217,000 | 34,857,000 | 11,337,000 | 22,670,000 |
| Mar 2026 | 300,000 | — | -2,127,000 | -2,044,000 | 38,248,000 | 14,431,000 | 22,849,000 |
| Dec 2025 | 0 | — | -2,063,000 | -1,996,000 | 38,239,000 | 13,056,000 | 22,856,000 |
| Sep 2025 | 0 | — | -4,440,000 | -4,361,000 | 30,836,000 | 7,528,000 | 24,098,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,742,000
Investing CF
$-19,000
Financing CF
$12,162,000
CapEx
$-19,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.50
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-363,971,000
Inventory
—
Receivables
$1,809,000
ST Investments
—
EBIT TTM
$-11,925,000
Pretax Income TTM
$-11,617,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$300,000
EBITDA
$-9,699,000
Free Cash Flow
$-7,776,500
Enterprise Value
$1,567,133
Total Cash
$8,473,000
Total Debt
$3,427,000
Shares Out
45,892,668
Trailing EPS
$0.73
Book Value
$0.23
ROE
-99.8%
ROA
-19.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -24,051,000 | -23,739,000 | 38,239,000 | 22,856,000 | 15,383,000 | -16,669,000 |
| Dec 2024 | 0 | -19,427,000 | -25,653,000 | 35,352,000 | 16,285,000 | 19,067,000 | -16,937,000 |
| Dec 2023 | 0 | -21,431,000 | -18,349,000 | 55,219,000 | 15,522,000 | 39,697,000 | -18,996,000 |
| Dec 2022 | 0 | -21,581,000 | -19,685,000 | 71,861,000 | 17,297,000 | 54,564,000 | -19,082,000 |
TTM Snapshot
Revenues TTM
$516,000
NetIncome TTM
$-13,128,000
OpCashFlow TTM
—
Assets (Latest)
$34,857,000
Forward EPS
$-0.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| APRE | Aprea Therapeutics, Inc. | $6.43M | $0.45 | — |
| ENVB | Enveric Biosciences, Inc. | $6.31M | $1.41 | — |
| TPST | Tempest Therapeutics, Inc. | $6.54M | $0.33 | — |
| CVKD | Cadrenal Therapeutics, Inc. | $6.71M | $1.88 | — |
| SNGX | SOLIGENIX, INC. | $6.11M | $0.28 | — |
News headlines (Yahoo Finance, 1h cache)
Theriva Biologics: Q3 Earnings Snapshot
2026-11-12 13:09 · Yahoo
Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results
2026-11-12 13:00 · Yahoo
Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.
2026-11-02 13:00 · Yahoo
Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine
2026-09-30 12:00 · Yahoo
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
2026-08-11 12:00 · Yahoo
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancre
2026-08-06 12:00 · Yahoo
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients wi
2026-07-07 12:00 · Yahoo
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
2026-06-11 12:00 · Yahoo
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
2026-04-17 20:05 · Yahoo
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
2026-05-05 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.